Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EC Ecopetrol SA

Trading 08-24 14:59:17 EDT

17.29

-0.24

-1.37%

High17.33	Low17.06	Vol756.68K
Open17.23	D1 Closing17.53	Amplitude1.54%
Mkt Cap35.55B	Tradable Cap4.10B	Total Shares2.06B
T/O13.03M	T/O Rate0.32%	Tradable Shares237.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EC","market":"US","secType":"STK","nameCN":"Ecopetrol SA","latestPrice":17.29,"timestamp":1787597955387,"preClose":17.53,"halted":0,"volume":756677,"delay":0,"changeRate":-0.013690815744438218,"floatShares":237000000,"shares":2055834734,"eps":1.903,"marketStatus":"Trading","change":-0.24,"latestTime":"08-24 14:59:17 EDT","open":17.23,"high":17.33,"low":17.06,"amount":13025561.216350999,"amplitude":0.015402,"askPrice":17.29,"askSize":225,"bidPrice":17.27,"bidSize":400,"shortable":3,"etf":0,"ttmEps":1.903,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":1,"adrRate":20,"listingDate":1221710400000,"exchange":"NYSE","adjPreClose":17.53,"dividendRate":0.057316,"preHourTrading":{"tag":"盘前","latestPrice":17.55,"preClose":17.53,"latestTime":"09:06 EDT","volume":295,"amount":5110.82013,"timestamp":1787576787333,"change":0.02,"changeRate":0.001141,"amplitude":0.022818},"postHourTrading":{"tag":"盘后","latestPrice":17.34,"preClose":17.53,"latestTime":"19:52 EDT","volume":16073,"amount":281727.6855,"timestamp":1787356322317,"change":-0.19,"changeRate":-0.010839,"amplitude":0.015402},"volumeRatio":0.657614,"impliedVol":0.3814,"impliedVolPercentile":0.1793},"requestUrl":"/m/hq/s/EC/wiki","defaultTab":"wiki","newsList":[{"id":"2661627957","title":"Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627957","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627957?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":"-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --  BOSTON, Aug.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349657/0/en/rhythm-pharmaceuticals-announces-mhlw-approval-of-imcivree-setmelanotide-for-patients-with-acquired-hypothalamic-obesity-ho-in-japan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201","VUS","BMI","AVP","BK4157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661645502","title":"EC Healthcare shareholders unanimously back AGM resolutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2661645502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661645502?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:12","pubTimestamp":1787307163,"startTime":"0","endTime":"0","summary":"An update from EC Healthcare ( ($HK:2138) ) is now available. EC Healthcare has announced that all resolutions put to shareholders at its annual ge...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ec-healthcare-shareholders-unanimously-back-agm-resolutions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ec-healthcare-shareholders-unanimously-back-agm-resolutions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","AGM","XBI","BK4201","BK4585","LABU","LU0029874061.USD","EC","BK4588","XLV","HCSG","BK4195","LU0128526141.USD","BK4229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660451302","title":"Press Release: Ecopetrol Completes Acquisition of a Controlling 51% Stake in Brava Energia S.A. and Strengthens Its Growth Platform in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2660451302","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660451302?lang=en_us&edition=fundamental","pubTime":"2026-08-18 12:21","pubTimestamp":1787026860,"startTime":"0","endTime":"0","summary":"BOGOT, Aug. 18, 2026 /PRNewswire/ -- Ecopetrol S.A.   announces that, through its wholly owned subsidiary Ecopetrol Investimentos do Brasil Ltda. , it has completed the acquisition of a controlling interest equivalent to approximately 51% of the outstanding voting share capital of Brava Energia S.A. . The closing of the Transaction followed the satisfaction of all applicable regulatory approvals and other conditions precedent required under the terms described below.The Transaction represents a significant milestone in the execution of Ecopetrol's growth, strengthening, and portfolio diversification strategy. It expands the Company's presence in Brazil, one of the most dynamic energy markets in the region and adds a substantial reserve and production base intended to enhance the Company's capacity to generate long-term value for its shareholders.The Transaction was completed through the following milestones achieved on the date of this report:-- Settlement and payment of the voluntary ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PXE","EC","EWZS","BK4588","IXC","DRIP","XES","ERX","PXJ","BK4201","USE","IEO","VDE","GUSH","DIG","BK4585","DBC","DRLL","FTXN","WTIU","DBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848797","title":"Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848797","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848797?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:00","pubTimestamp":1786968000,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346041/0/en/rhythm-pharmaceuticals-announces-appointment-of-manher-aj-joshi-as-chief-medical-officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889566641.SGD","LU2098885051.SGD","BK4561","LU0823411888.USD","LU1267930573.SGD","VUS","IE00BYQQ9H92.USD","LU0128525689.USD","AVP","LU1267930227.SGD","IE00BFXG0V08.USD","LU0052756011.USD","BK4566","BK4581","LU0792757196.USD","BK4534","LU1303367103.USD","BK4201","NKE","STYL","LU0786609619.USD","LU0708994859.HKD","BK4146","LU0029864427.USD","LU0128525929.USD","LU0310800379.SGD","BK4585","BK4588","BK4558","LU1267930813.SGD","LU0310800965.SGD","BK4533","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659843142","title":"UBS Adjusts Ecopetrol Price Target to $16 From $14, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659843142","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659843142?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:35","pubTimestamp":1786714507,"startTime":"0","endTime":"0","summary":"Ecopetrol (EC) has an average rating of hold and mean price target of $15.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4201","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144364","title":"UBS Sticks to Their Hold Rating for Ecopetrol SA (EC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144364?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:56","pubTimestamp":1786712204,"startTime":"0","endTime":"0","summary":"UBS analyst maintained a Hold rating on Ecopetrol SA today and set a price target of $16.00. Currently, the analyst consensus on Ecopetrol SA is a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-their-hold-rating-for-ecopetrol-sa-ec-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-sticks-to-their-hold-rating-for-ecopetrol-sa-ec-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907724","title":"Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907724","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907724?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"Arm 3 with ultra-low dose gemcitabine sensitization) in the. registrational-intent Phase 2b study, across both US and European. -- Two presentations at the American Association for Cancer Research . Annual Meeting highlighted data showing the underlying molecular. mechanisms for potent synergies between ACR-368 and immune checkpoint. AP3. These findings support the potential for clinical combination. studies with antibody-drug conjugates  or ICIs.ACR-2316-- ACR-2316 advanced into the randomized dose expansion stage of the Phase. 1/2 study, supported by observed favorable safety profile and durable. antitumor activity. The expansion phase is evaluating 120 mg and 160 mg. doses, administered orally, once-daily  utilizing a 3d on / 4d off. -- Dose expansion phase will assess safety and activity in subjects with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4201","BK4139","EC","ACRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659779159","title":"City Developments' Patmi triples in 1HFY2026; strategic review by end of Sept","url":"https://stock-news.laohu8.com/highlight/detail?id=2659779159","media":"The Edge Singapore ","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659779159?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:36","pubTimestamp":1786548964,"startTime":"0","endTime":"0","summary":"City Developments' Patmi tripled in 1HFY2026, supported by property development. The board declared an interim dividend of 6 cents while NAV stood at $10.74 as at June 30. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/capital/results/city-developments-patmi-triples-1hfy2026-strategic-review-end-sept?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/capital/results/city-developments-patmi-triples-1hfy2026-strategic-review-end-sept?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["ACKY","BK6512","SG9999016042.SGD","EC","CDL","SGXZ24219693.SGD","BK4201","BK4127","BK6098","C09.SI","SG9999000475.SGD","TOP","SG9999006266.SGD","ACTV","SG9999000343.SGD","SGXZ43160589.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658902819","title":"Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658902819","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658902819?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449600,"startTime":"0","endTime":"0","summary":"-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --BOSTON, Aug.  11, 2026  (GLOBE NEWSWIRE) -- Rhythm Phar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342640/0/en/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-authorization-in-the-united-kingdom-for-treatment-of-obesity-and-control-of-hunger-in-patients-w.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4201","EC","BK4157","BMI","AVP","UBCP","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657859567","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2657859567","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657859567?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:01","pubTimestamp":1785873660,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  04, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338772/0/en/Rhythm-Pharmaceuticals-Announces-Participation-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVP","EC","BK4201","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558874","title":"Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558874?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:01","pubTimestamp":1785841260,"startTime":"0","endTime":"0","summary":"-- U.S. launch of IMCIVREE (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338168/0/en/Rhythm-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU0971096721.USD","LU2237443895.HKD","LU2237443549.SGD","LU2237443382.USD","VUS","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","LU0882574139.USD","LU2237443978.SGD","CMC","LU0170899867.USD","PWS","LU2746668461.USD","IE00BHPRN162.USD","LU2746668974.SGD","BK4006","LU0267386448.USD","BK4201","IE00BZ1G4Q59.USD","LU0149725797.USD","LU1363072403.SGD","LU2237443622.USD","IE00BFXG1179.USD","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558369","title":"Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558369","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558369?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:55","pubTimestamp":1785840900,"startTime":"0","endTime":"0","summary":"-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon -- -- Management to host conference call to discuss second quarter 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338126/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Data-from-Phase-2-Trial-that-Showed-RM-718-Demonstrated-Positive-Efficacy-Signal-in-Acquired-Hypothalamic-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","VUS","AVP","EC","BK4166","RM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655384930","title":"Karyopharm down 69% after XPORT-EC-042 trial did not meet primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2655384930","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655384930?lang=en_us&edition=fundamental","pubTime":"2026-07-31 06:20","pubTimestamp":1785450020,"startTime":"0","endTime":"0","summary":"18:19 EDT Karyopharm (KPTI) down 69% after XPORT-EC-042 trial did not meet primary endpoint Published first on TheFly – the ultimate source for rea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/karyopharm-down-69-after-xport-ec-042-trial-did-not-meet-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/karyopharm-down-69-after-xport-ec-042-trial-did-not-meet-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4201","EC","KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655871907","title":"Agios Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655871907","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655871907?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:30","pubTimestamp":1785407400,"startTime":"0","endTime":"0","summary":"Mitapivat (PYRUKYND and AQVESME) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335866/31990/en/Agios-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU0971096721.USD","GB00B4QBRK32.GBP","LU2237443895.HKD","LU2237443549.SGD","LU0823417653.USD","LU2237443382.USD","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","LU0882574139.USD","BK4504","GCC","LU0114720955.EUR","SYK","LU2237443978.SGD","CMC","LU0170899867.USD","LU2506952170.USD","LU2468319806.SGD","LU2404859667.USD","LU0882574055.USD","BK4566","IE00BHPRN162.USD","LU2362541273.HKD","LU2404859741.USD","LU2362540622.SGD","LU2506951958.HKD","LU2089984988.USD","LU2746668974.SGD","LU0058720904.USD","BK4156","BK4199","LU0528227936.USD","BK4006","LU0267386448.USD","IE00BZ1G4Q59.USD","IHI","ITP","LU0289739699.SGD","LU2324357040.USD","LU0432979614.USD","BK4082","LU1363072403.SGD","LU2237443622.USD","IE00BFXG1179.USD","LU0690374615.EUR","LU0950375773.USD","LU1791710400.SGD","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655384781","title":"Press Release: Pharming Reports Second Quarter and First Half 2026 Financial Results and Revises Year-end Guidance; Strong Joenja Momentum and Near-term Clinical Readouts to Support Broader Therapeutic Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2655384781","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655384781?lang=en_us&edition=fundamental","pubTime":"2026-07-30 13:00","pubTimestamp":1785387600,"startTime":"0","endTime":"0","summary":"For investor audiences and media only-- Second quarter 2026 total revenues decreased by 3% to US$90.2 million,-- RUCONEST revenue was US$72.3 million, a 10% decrease compared to the. second quarter 2025 and a 24% increase compared to the first quarter. 2026, with active patient base 93% of year-ago and strong new patient. -- Joenja revenue was US$17.9 million, a 40% increase compared to the. second quarter 2025, reflecting continued strong U.S. and international. growth, with first European launch in Germany after quarter-end. -- Second quarter operating profit amounted to US$1.3 million compared to. US$10.8 million in the second quarter 2025, impacted by. -- Plans to report clinical data with leniolisib in significantly larger. CVID patient populations in the fourth quarter 2026. -- Updates 2026 total revenue guidance to US$375 million - US$395 million,reflecting a US$30 million reduction, and improves operating expense. guidance by US$15 million to US$315 million - US$320 million","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFMHRM44.USD","LU0128526141.USD","BK4530","BK4201","LU0757428866.USD","CRL","BK4588","PHAR","BK4585","BK4022","LU0029874061.USD","EC","R","BK4139","BK4121","BK4232","LU0390134368.USD","EEA","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655660238","title":"Incyte says EC approves Opzelura cream for treatment of AD","url":"https://stock-news.laohu8.com/highlight/detail?id=2655660238","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655660238?lang=en_us&edition=fundamental","pubTime":"2026-07-29 18:20","pubTimestamp":1785320455,"startTime":"0","endTime":"0","summary":"Incyte (INCY) announced that the European Commission has approved Opzelura cream for the treatment of moderate atopic dermatitis in adult patients ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incyte-says-ec-approves-opzelura-cream-for-treatment-of-ad-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incyte-says-ec-approves-opzelura-cream-for-treatment-of-ad-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4201","EC","EPV","BK4532","BK4550","INCY","BK4132","AD","IDNA","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167631876","title":"Earning Preview: Ecopetrol SA Q2 revenue is expected to increase by 39.77%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1167631876","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167631876?lang=en_us&edition=fundamental","pubTime":"2026-07-28 00:12","pubTimestamp":1785168730,"startTime":"0","endTime":"0","summary":"Abstract Ecopetrol SA will report quarterly results on August 03, 2026 Post Market; this preview summarizes consensus forecasts for revenue, margins, and EPS alongside segment dynamics and recent...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Ecopetrol SA Q2 revenue is expected to increase by 39.77%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653765517","title":"The EU’s 50bn alley-oop to BECCS projects in the Pulp & Paper industry","url":"https://stock-news.laohu8.com/highlight/detail?id=2653765517","media":"Fastmarkets","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653765517?lang=en_us&edition=fundamental","pubTime":"2026-07-22 12:00","pubTimestamp":1784692800,"startTime":"0","endTime":"0","summary":"The EU ETS carbon removals mechanism channels most of its purchasing power toward BECCS, and Europe’s biogenic CO2 point sources sit in the pulp and paper industry.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fastmarkets_highlight","url":"https://www.fastmarkets.com/insights/the-eus-50bn-alley-oop-to-beccs-projects-in-the-pulp-paper-industry/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fastmarkets.com/insights/the-eus-50bn-alley-oop-to-beccs-projects-in-the-pulp-paper-industry/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fastmarkets_highlight","symbols":["CCS","BK4088","BK4570","EC","BK4201","PPI","BK4156","ETS","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653927705","title":"Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653927705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653927705?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635200,"startTime":"0","endTime":"0","summary":"BOSTON, July  21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330408/0/en/Rhythm-Pharmaceuticals-to-Report-Second-Quarter-2026-Financial-Results-on-Tuesday-August-4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVP","VUS","BK4201","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653524725","title":"Press Release: Ecopetrol Resumes the Tender Offer in Brazil to Complete the Acquisition of a Controlling Equity Stake in Brava Energia S.A.","url":"https://stock-news.laohu8.com/highlight/detail?id=2653524725","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653524725?lang=en_us&edition=fundamental","pubTime":"2026-07-21 09:48","pubTimestamp":1784598480,"startTime":"0","endTime":"0","summary":"BOGOT, Colombia, July 20, 2026 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) announced today that its Brazilian subsidiary, Ecopetrol Investimentos do Brasil LTDA, published on the B3 Secu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","EQR","EC","EWZS","REZ","BK4585","BK4588","BK4201"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ecopetrol.com.co","stockEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":0.0503},{"period":"3month","weight":0.2657},{"period":"6month","weight":0.4024},{"period":"1year","weight":0.9697},{"period":"ytd","weight":0.7495}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ecopetrol S.A. operates as an integrated energy company. The company operates through four segments: Exploration and Production; Transport and Logistics; Refining, Petrochemical and Biofuels; and Electric Power Transmission and Toll Roads Concessions. It engages in the exploration and production of oil and gas; transportation of crude oil, motor fuels, fuel oil, and other refined products, including diesel, jet, and biofuels; processing and refining crude oil; distribution of natural gas and LPG; sale of refined and petrochemical products; supplying of electric power transmission services; design, development, construction, operation, and maintenance of road and energy infrastructure projects; and supplying of information technology and telecommunications services. As of December 31, 2022, the company had approximately 9,127 kilometers of crude oil and multi-purpose pipelines. It also produces and commercializes polypropylene resins and compounds, and masterbatches; and offers industrial service sales to customers and specialized management services. It has operations in Colombia, the United States, Asia, Central America and the Caribbean, Europe, and South America. The company was formerly known as Empresa Colombiana de Petróleos and changed its name to Ecopetrol S.A. in June 2003. Ecopetrol S.A. was incorporated in 1948 and is headquartered in Bogotá, Colombia.","yearOnYearQuotes":[{"month":1,"riseRate":0.611111,"avgChangeRate":0.047964},{"month":2,"riseRate":0.5,"avgChangeRate":0.012901},{"month":3,"riseRate":0.722222,"avgChangeRate":0.035116},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.012129},{"month":5,"riseRate":0.388889,"avgChangeRate":-0.01423},{"month":6,"riseRate":0.444444,"avgChangeRate":0.004017},{"month":7,"riseRate":0.5,"avgChangeRate":0.017041},{"month":8,"riseRate":0.5,"avgChangeRate":0.00328},{"month":9,"riseRate":0.470588,"avgChangeRate":-0.011239},{"month":10,"riseRate":0.611111,"avgChangeRate":-0.007073},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.030395},{"month":12,"riseRate":0.611111,"avgChangeRate":0.009975}],"exchange":"NYSE","name":"Ecopetrol SA","nameEN":"Ecopetrol SA","securityTypeName":"DR","adrRate":"1:20"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ecopetrol SA(EC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ecopetrol SA,EC,Ecopetrol SA股票,Ecopetrol SA股票老虎,Ecopetrol SA股票老虎国际,Ecopetrol SA行情,Ecopetrol SA股票行情,Ecopetrol SA股价,Ecopetrol SA股市,Ecopetrol SA股票价格,Ecopetrol SA股票交易,Ecopetrol SA股票购买,Ecopetrol SA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ecopetrol SA(EC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction